A5004328787- Chromatin Remodeling and Cancer
- Cancer Mechanisms and Therapy
- Protein Degradation and Inhibitors
- Peptidase Inhibition and Analysis
- Mechanisms of cancer metastasis
- Research on Leishmaniasis Studies
- Epigenetics and DNA Methylation
- Cancer-related gene regulation
- Renin-Angiotensin System Studies
- Virus-based gene therapy research
- Dialysis and Renal Disease Management
- Chemokine receptors and signaling
- Peripheral Artery Disease Management
- Healthcare Systems and Public Health
- Vitamin D Research Studies
- Bone health and osteoporosis research
- Renal Diseases and Glomerulopathies
- Autoimmune Bullous Skin Diseases
- Neuroscience and Neuropharmacology Research
- Cytokine Signaling Pathways and Interactions
- Traditional Chinese Medicine Analysis
- Platelet Disorders and Treatments
- Bioactive Compounds and Antitumor Agents
- Human Health and Disease
- Blood properties and coagulation
Ningbo University
2024
Morpho (United States)
2024
Constellation Pharmaceuticals (United States)
2024
Shanghai Jiao Tong University
2018-2022
Ruijin Hospital
2018
Keele University
2012
Royal Stoke University Hospital
2012
Abstract Recurrent somatic mutations in the BRG1/BRM-associated factor (BAF) chromatin remodeling complex subunit ARID1A occur frequently advanced urothelial, endometrial, and ovarian clear cell carcinomas, creating an alternative state that may be exploited therapeutically. The histone methyltransferase EZH2 has been previously identified as targetable vulnerability context of mutations. In this study, we describe discovery tulmimetostat, orally available, clinical stage inhibitor, it...
Inflammation, hypoalbuminaemia and peritoneal protein clearance are important predictors of survival in patients treated with dialysis (PD). We hypothesized that the common link is abnormal endothelial barrier function. To test this, we explored associations between hypoalbuminaemia, systemic albumin leak soluble markers inflammation injury.This was a cross-sectional study 41 prevalent PD patients. Endothelial function measured as transcapillary escape rate (125)I [transcapillary...
<div>Abstract<p>Recurrent somatic mutations in the BRG1/BRM-associated factor (BAF) chromatin remodeling complex subunit ARID1A occur frequently advanced urothelial, endometrial, and ovarian clear cell carcinomas, creating an alternative state that may be exploited therapeutically. The histone methyltransferase EZH2 has been previously identified as targetable vulnerability context of mutations. In this study, we describe discovery tulmimetostat, orally available, clinical stage...
<p>Tulmimetostat mediated cancer cell phenotypic responses are increased in ARID1A LOF contexts.</p>
<p>Synthetic pathway and characterization of tulmimetostat, a long residence time EZH2 inhibitor.</p>
<p>Additional method information to describe technical aspects of the experiments described in this manuscript</p>
<p>Tulmimetostat demonstrates superior level of tumor PRC2 target gene inducon and correlation with efficacy in a bladder cancer xenograft mouse model.</p>
<p>Tulmimetostat demonstrates superior level of tumor PRC2 target gene inducon and correlation with efficacy in a bladder cancer xenograft mouse model.</p>
<p>In cancer patients tulmimetostat plasma exposure levels correlate with PRC2 target gene expression changes in peripheral blood.</p>
<p>Tulmimetostat improves cisplatin responsiveness in chemotherapy-resistant bladder cancer cells.</p>
<p>Synthetic pathway and characterization of tulmimetostat, a long residence time EZH2 inhibitor.</p>
<div>Abstract<p>Recurrent somatic mutations in the BRG1/BRM-associated factor (BAF) chromatin remodeling complex subunit ARID1A occur frequently advanced urothelial, endometrial, and ovarian clear cell carcinomas, creating an alternative state that may be exploited therapeutically. The histone methyltransferase EZH2 has been previously identified as targetable vulnerability context of mutations. In this study, we describe discovery tulmimetostat, orally available, clinical stage...
<p>Additional method information to describe technical aspects of the experiments described in this manuscript</p>
<p>In cancer patients tulmimetostat plasma exposure levels correlate with PRC2 target gene expression changes in peripheral blood.</p>